A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors offers a promising strategy against patient-specific cancer cells Cancerous melanoma cells shown with their cell bodies and nuclei are nestled in tiny hollow lumens within the polymeric cryogel structure. Credit: Wyss Institute at Harvard University New research led by Wyss Core Faculty member David Mooney, Ph.D., in collaboration with researchers at the Dana-Farber Cancer Institute could potentially yield a new platform for cancer vaccines.